前沿生物(688221.SH)：2025年净亏损2.62亿元

Core Viewpoint - Frontier Biotech (688221.SH) reported a total operating revenue of 1,436.687 million yuan for the year 2025, reflecting a year-on-year growth of 10.96% driven by sales of innovative HIV drug Aikening® (generic name: Abacavir), the agency product Veklury® (remdesivir), and the newly approved far-infrared therapy patch Xiaoyan Yipian® [1] Financial Performance - The company recorded a net loss attributable to shareholders of the parent company amounting to 261.7174 million yuan, which is an increase in loss by 60.3348 million yuan compared to the previous year, primarily due to the absence of investment income from the disposal of subsidiary equity that generated 71.8365 million yuan in the previous year [1] - The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 296.2409 million yuan, which is a reduction in loss by 31.0703 million yuan year-on-year, mainly due to the increase in operating revenue and a decrease in period expenses [1]